Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-GY036: One vs. Two Years of Maintenance Olaparib With or Without Bevacizumab in BRCA/HRD+ Ovarian Cancer
jRCT1031250319Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Investigator-assessed progression-free survival (PFS) by RECIST v1.1 (non-inferiority). Started Sep 2025; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT1031250319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250319.